Elsevier

Journal of Hepatology

Volume 65, Issue 2, August 2016, Pages 425-443
Journal of Hepatology

Review
Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications

https://doi.org/10.1016/j.jhep.2016.04.005Get rights and content

Summary

Non-alcoholic fatty liver disease (NAFLD) has become one of the most frequent chronic liver diseases in the Western society and its prevalence is likely to rise even further. An increasing body of evidence shows that NAFLD is not only a potentially progressive liver disease, but also has systemic consequences. More specifically, evidence points out that NAFLD has to be considered as a significant independent risk factor for subclinical and clinical cardiovascular disease (CVD). Long-term follow-up studies demonstrate cardiovascular mortality to be the most important cause of death in NAFLD patients. Moreover, ample evidence associates NAFLD with endothelial dysfunction, increased pulse wave velocity, increased coronary arterial calcifications and increased carotid intima media thickness, all established markers for CVD.

Despite of all this evidence, the mechanisms by which NAFLD causally contributes to CVD are not fully elucidated. Furthermore, an extensive overview of all potential pathophysiological mechanisms and the corresponding current data are lacking. In this review we summarise current knowledge, originating from fundamental and clinical research, that mechanistically links NAFLD to CVD. Subsequently, the impact of CVD on current clinical practice and future research in the area of NALFD are discussed.

Introduction

Non-alcoholic fatty liver disease (NAFLD) has become a major cause of chronic liver disease in Western societies and will become the main underlying cause for liver transplantation within 10 years [1]. Although awareness amongst physicians has increased and the importance is recognised, levels of screening and referral to hepatologists in suspected NAFLD is low in primary care and non-hepatology specialties [2], [3]. As a result, NAFLD is relatively underdiagnosed and long-term outcomes of hepatic and extrahepatic manifestations of NAFLD are compromised. Indeed, NAFLD is not only associated with increased liver-related morbidity and mortality, but also with increased mortality due to cardiovascular disease (CVD) and cancer [4], [5].

Increased cardiovascular mortality and morbidity are observed in NAFLD.

The role of NAFLD as an independent cardiovascular risk factor is still debated. Several studies demonstrated unequivocally an increased cardiovascular (CV) mortality in NAFLD [4], [6]. Nevertheless, some studies failed to confirm this association, including two large cohort studies with long-term follow-up [7], [8]. However, the data should be interpreted with caution because of several methodological issues, including retrospective diagnosis based on recorded ultrasound imaging or on biochemistry [7], which is known to poorly correlate with histological NAFLD features [9]. Even in the absence of a significant relation with CV mortality, CVD was still undoubtedly increased in NALFD patients compared to controls [8], supporting the many convincing data that NAFLD independently contributes to (sub)clinical CVD.

Distillation of NAFLD as a separate risk factor is impeded by overlap with other well-established risk factors for CVD, as they are also risk factors for NAFLD itself [5]. Assuming that NAFLD is a contributor to CVD implies the need for knowledge on the underlying pathophysiological mechanisms that explain how NAFLD independently impacts on CVD. An extensive overview of potential mechanisms is currently lacking.

In this review we summarise knowledge, originating from animal research as well as translational and clinical research, about the underlying pathophysiological mechanisms that might link NAFLD to CVD. We subsequently discuss the potential implications of these findings for clinical management of patients with NAFLD and future research goals.

Section snippets

General considerations

The specific contribution of NAFLD to increased CVD risk is, especially in clinical studies, difficult to dissect from the combination of risk factors that are shared by both NAFLD and CVD. The population of NAFLD patients is furthermore probably heterogeneous, in some of whom NAFLD is just part of and victim of the global metabolic derangement whilst in others, the liver is particularly involved in the pathophysiology of the Metabolic Syndrome (MetS) itself, and in the emergence of CVD and

Potential pathophysiological mechanisms

The mechanisms explaining development of CVD in NAFLD are not completely understood. NAFLD is part of a complex multisystem disease with multiple bidirectional relationships. Moreover, each individual patient might exhibit a unique combination of causal mechanisms. The next section summarises the different potential mechanisms by which NAFLD may contribute to CVD (Fig. 2; Table 1). These mechanisms are rather complex, incompletely known and often interrelated.

Current guidelines

In the current published recommendations, both on the clinical management of the patients with NAFLD and a fortiori on the design of therapeutic trials for NAFLD, the link with CVD disease is not a major issue [180], [181], [182]. In the clinical guidelines, the overt link of NAFLD with the MetS translates into instructions to screen NAFLD patients for associated CVRFs and to treat these according to their proper guidelines [15]. In the joined AASLD-AGA guidelines, these instructions are only

Conclusions

The liver and the cardiovascular system are inextricably linked to each other: the hepato-cardiovascular axis.

CVD remains the most important cause of death in patients with NAFLD. Clinical evidence for a hepato-cardiovascular axis, in which NAFLD is an independent risk factor for subclinical and clinical CVD is supported by evidence from fundamental and clinical research; unravelling the mechanisms by which NAFLD causally influences endothelial dysfunction and the development of atherosclerosis

Financial support

WK and SF received funding from the fund for scientific research (FWO) flanders (11j9513n, 1802154n). The funders had no role in the preparation of the manuscript.

Conflict of interest

The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

Authors’ contributions

All authors contributed to the draft of the text. Furthermore, the intellectual content was subject to critical review by SF and WK. DG created the figures.

References (215)

  • C.D. Byrne et al.

    NAFLD: a multisystem disease

    J Hepatol

    (2015)
  • S. Francque et al.

    Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture

    Lab Invest

    (2012)
  • M. Sunbul et al.

    Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness

    Atherosclerosis

    (2014)
  • Y. Iwakiri et al.

    Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions

    J Hepatol

    (2014)
  • E. Maslak et al.

    Liver sinusoidal endothelial cells (LSECs) function and NAFLD; NO-based therapy targeted to the liver

    Pharmacol Rep

    (2015)
  • M. Pasarín et al.

    Insulin resistance and liver microcirculation in a rat model of early NAFLD

    J Hepatol

    (2011)
  • T. Kasumov et al.

    Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease

    Metabolism

    (2011)
  • S. Hirsch et al.

    Serum folate and homocysteine levels in obese females with non-alcoholic fatty liver

    Nutrition

    (2005)
  • S.A. Polyzos et al.

    Serum homocysteine levels in patients with nonalcoholic fatty liver disease

    Ann Hepatol

    (2012)
  • F. Santilli et al.

    Homocysteine, methylenetetrahydrofolate reductase, folate status and atherothrombosis: a mechanistic and clinical perspective

    Vascul Pharmacol

    (2016)
  • N.V. Leach et al.

    Serum homocysteine levels, oxidative stress and cardiovascular risk in non-alcoholic steatohepatitis

    Eur J Intern Med

    (2014)
  • A. Sonmez et al.

    Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease

    J Clin Lipidol

    (2015)
  • S. Coulon et al.

    Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease

    Cytokine

    (2012)
  • Y. Yilmaz et al.

    Circulating levels of vascular endothelial growth factor A and its soluble receptor in patients with biopsy-proven nonalcoholic fatty liver disease

    Arch Med Res

    (2011)
  • S. Ylä-Herttuala et al.

    Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine

    J Am Coll Cardiol

    (2007)
  • R. Loeffen et al.

    The impact of blood coagulability on atherosclerosis and cardiovascular disease

    J Thromb Haemost

    (2012)
  • S. Sookoian et al.

    Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease

    Atherosclerosis

    (2010)
  • A. Tripodi et al.

    Procoagulant imbalance in patients with non-alcoholic fatty liver disease

    J Hepatol

    (2014)
  • C.-J. Bergqvist et al.

    Awareness and opinions of non-alcoholic fatty liver disease by hospital specialists

    Intern Med J

    (2013)
  • M. Ekstedt et al.

    Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

    Hepatology

    (2015)
  • S.K. Satapathy et al.

    Epidemiology and natural history of nonalcoholic fatty liver disease

    Semin Liver Dis

    (2015)
  • C. Söderberg et al.

    Decreased survival of subjects with elevated liver function tests during a 28-year follow-up

    Hepatology

    (2010)
  • M. Lazo et al.

    Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study

    BMJ

    (2011)
  • S. Verma et al.

    Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)

    Liver Int

    (2013)
  • A. Kotronen et al.

    Fatty liver: a novel component of the metabolic syndrome

    Arterioscler Thromb Vasc Biol

    (2008)
  • H. Tilg et al.

    Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis

    Hepatology

    (2010)
  • L. Heilbronn et al.

    Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus

    Int J Obes Relat Metab Disord

    (2004)
  • D.E. Kleiner et al.

    Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research

    Semin Liver Dis

    (2012)
  • S. Singh et al.

    Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies

    Clin Gastroenterol Hepatol

    (2015)
  • P. Angulo et al.

    Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease

    Gastroenterology

    (2015)
  • M. Ekstedt et al.

    Long-term follow-up of patients with NAFLD and elevated liver enzymes

    Hepatology

    (2006)
  • G. Musso et al.

    Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

    Ann Med

    (2011)
  • V. Ratziu et al.

    Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

    Gastroenterology

    (2016)
  • I. Ying et al.

    Nonalcoholic fatty liver disease and acute ischemic stroke

    Epidemiology

    (2011)
  • M. Boddi et al.

    Nonalcoholic fatty liver in nondiabetic patients with acute coronary syndromes

    Eur J Clin Invest

    (2013)
  • N. Villanova et al.

    Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease

    Hepatology

    (2005)
  • M.T. Long et al.

    Nonalcoholic fatty liver disease and vascular function: cross-sectional analysis in the Framingham heart study

    Arterioscler Thromb Vasc Biol

    (2015)
  • B.M. Kaess et al.

    Aortic stiffness, blood pressure progression, and incident hypertension

    JAMA

    (2012)
  • S.A. Madan et al.

    Nonalcoholic fatty liver disease and carotid artery atherosclerosis in children and adults: a meta-analysis

    Eur J Gastroenterol Hepatol

    (2015)
  • E. Bonci et al.

    Association of nonalcoholic fatty liver disease with subclinical cardiovascular changes: a systematic review and meta-analysis

    Biomed Res Int

    (2015)
  • Cited by (359)

    View all citing articles on Scopus
    View full text